Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Total Liabilities
Everything the company owes to creditors and other parties.
Citius Oncology, Inc.NASDAQ: CTOR
Total Liabilities · Q2 FY2026 · quarter ended Mar 2026
Total liabilities rises 17.3% from a year ago
Total liabilities stood at $65.43M at the end of Q2 FY2026, up 17.3% from a year earlier and up 26.9% from the prior quarter. Over 3 fiscal years it compounded at +105.9% a year.
Context
- Total liabilities amounted to 65.0% of total assets at the end of Q2 FY2026, up 4.0 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +17.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 56.08M USD
- Year-over-year change
- +46.7%
- 3-year CAGR
- +105.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 56.08M | +46.7% |
| FY2024 | 2024-09-30 | 38.23M | +72.2% |
| FY2023 | 2023-09-30 | 22.2M | +245.6% |
| FY2022 | 2022-09-30 | 6.42M | — |
Total Liabilities vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 total liabilities of $65.43M is the 5th highest of the 10 companies compared; the peer median is $50.91M.
- Its year-over-year change of +17.3% is the 4th highest of 10, against a peer median of -19.7%.
- Total liabilities amounts to 65.0% of total assets for CTOR, versus a peer median of 58.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $657.17M | +1419.7% | +134.5% | 129.7% | |
| Mar 2026 | $547.71M | +88.6% | +125.5% | 186.5% | |
| Mar 2026 | $105.21M | -4.6% | -20.4% | 36.9% | |
| Mar 2026 | $91.12M | -19.9% | -34.7% | 77.5% | |
CTORCitius Oncology, Inc. | Mar 2026 | $65.43M | +17.3% | +105.9% | 65.0% |
| Mar 2026 | $50.91M | -19.7% | -9.9% | 58.7% | |
| Mar 2026 | $41.65M | -56.2% | +91.6% | 62.9% | |
| Mar 2026 | $25.12M | +178.2% | +90.0% | 37.4% | |
| Mar 2026 | $6.09M | -86.1% | -41.3% | 10.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $5.13M | -46.4% | +2.6% | 57.5% |
| Peer median (excluding CTOR) | $50.91M | -19.7% | +2.6% | 58.7% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.